Lung Cancer
Volume 69, Issue 1 , Pages 99-104 , July 2010

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer

  • Kyoichi Kaira

      Affiliations

    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 27 220 8136; fax: +81 27 220 8136.
    • ,
  • Noriaki Sunaga

      Affiliations

    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Yoshio Tomizawa

      Affiliations

    • Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, 2854 Kanai, Shibukawa, Gunma 377-8511, Japan
    • ,
  • Noriko Yanagitani

      Affiliations

    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Kimihiro Shimizu

      Affiliations

    • Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Hisao Imai

      Affiliations

    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Mitsuyoshi Utsugi

      Affiliations

    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Yasuki Iwasaki

      Affiliations

    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Hironobu Iijima

      Affiliations

    • Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, 2854 Kanai, Shibukawa, Gunma 377-8511, Japan
    • ,
  • Hiroaki Tsurumaki

      Affiliations

    • Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, 2854 Kanai, Shibukawa, Gunma 377-8511, Japan
    • ,
  • Akihiro Yoshii

      Affiliations

    • Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, 2854 Kanai, Shibukawa, Gunma 377-8511, Japan
    • ,
  • Naoto Fueki

      Affiliations

    • Jobu Hospital for Respiratory Disease 586-1 Taguchi-machi, Maebashi, Gunma 371-0048, Japan
    • ,
  • Takeshi Hisada

      Affiliations

    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Tamotsu Ishizuka

      Affiliations

    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Ryusei Saito

      Affiliations

    • Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, 2854 Kanai, Shibukawa, Gunma 377-8511, Japan
    • ,
  • Masatomo Mori

      Affiliations

    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan

Received 9 June 2009 ,Revised 22 August 2009 ,Accepted 28 September 2009.

References 

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30
  2. Tani N, Yabuki M, Komuro S, Kanamaru H. Characterization of the enzymes involved in the vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005;35:1121–1133
  3. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y. Cytotoxic amrubicinol on human tumor cells. Jpn J Cancer Res. 1998;89:1067–1073
  4. Ogawa M. Novel anticancer drugs in Japan. J Cancer Res Clin Oncol. 1999;125:134–140
  5. Kurata T, Okamoto I, Tamura K, Fukuoka M. Amrubicin for non-small-cell lung cancer and small-cell lung cancer. Invest New Drugs. 2007;25:499–504
  6. Okamoto I, Hamada A, Matsunaga Y, Sasaki J, Fujii S, Uramoto H, et al. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother Pharmacol. 2006;57:282–288
  7. Onoda S, Matsuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006;24:5448–5453
  8. Igawa S, Yamamoto N, Ueda S, Ono A, Nakamura Y, Tsuya A, et al. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol. 2007;2:741–744
  9. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26:5401–5406
  10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216
  11. Takeda K, Takifuji N, Negoro S, Furuse K, Nakamura S, Takada Y, et al. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) Study. Invest New Drugs. 2007;25:377–383
  12. Sawa T, Yana T, Takada M, Sugiura T, Kudoh S, Kamei T, et al. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small cell lung cancer (Study 1): a West Japan Thoracic oncology Group (WJTOG) trial. Invest New Drugs. 2006;24:151–158
  13. Igawa S, Takahashi T, Nakamura Y, Tsuya A, Ono A, Shukuya T, et al. Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy. Anticancer Res. 2008;26:3855–3858
  14. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, et al. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol. 1995;13:654–751
  15. Arango BA, Castrellon AB, Santos ES, Raez LE. Second-line therapy for non-small-cell lung cancer. Clin Lung Cancer. 2009;10:91–98
  16. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103
  17. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597
  18. Maio MD, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:1836–1843
  19. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease—The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15:2090–2096
  20. Eckardt JR, Bentsion DL, Lipatov ON, Polyakov IS, Mackintosh FR, Karlin DA, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol. 2009;20:2046–2051
  21. Shimokawa T, Shibuya M, Kitamura K, Hosomi Y, Hibino S, Ota T, et al. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. Int J Clin Oncol. 2009;14:63–69
  22. Ciuleanu T, Brodowicz T, Belani C, Kim J, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus nest supportive care (BSC) versus placebo plus BSC: a phase III study [abstract]. J Clin Oncol. 2008;26:426s

☆ Our clinical trial registration numbers are UMIN000001751 and UMIN000001752.

PII: S0169-5002(09)00496-6

doi: 10.1016/j.lungcan.2009.09.012

Lung Cancer
Volume 69, Issue 1 , Pages 99-104 , July 2010

Article Tools

* Image Usage & Resolution